Virtus ETF Advisers LLC Pmv Pharmaceuticals, Inc. Transaction History

Virtus ETF Advisers LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	SELL	$6.01 - $8.93 $9,916 - $14,734	-1,650 Reduced 9.07%	16,534 $101,000
Q2 2023 Aug 14, 2023	BUY	$3.94 - $6.27 $30,582 - $48,667	7,762 Added 74.48%	18,184 $113,000
Q1 2023 May 15, 2023	SELL	$4.77 - $9.16 $19,094 - $36,667	-4,003 Reduced 27.75%	10,422 $49,000
Q4 2022 Feb 14, 2023	BUY	$8.17 - $12.95 $27,483 - $43,563	3,364 Added 30.41%	14,425 $125,000
Q3 2022 Nov 14, 2022	BUY	$11.4 - $17.18 $855 - $1,288	75 Added 0.68%	11,061 $132,000
Q2 2022 Aug 12, 2022	BUY	$9.23 - $22.43 $39,135 - $95,103	4,240 Added 62.85%	10,986 $157,000
Q1 2022 May 16, 2022	SELL	$14.86 - $23.55 $6,018 - $9,537	-405 Reduced 5.66%	6,746 $140,000
Q4 2021 Feb 14, 2022	BUY	$19.99 - $30.24 $18,430 - $27,881	922 Added 14.8%	7,151 $165,000
Q3 2021 Nov 15, 2021	SELL	$26.84 - $36.58 $8,776 - $11,961	-327 Reduced 4.99%	6,229 $186,000
Q2 2021 Aug 10, 2021	BUY	$28.01 - $36.01 $183,633 - $236,081	6,556 New	6,556 $224,000

41.9M

3.1K

1.7K

Ticker PMVP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,622,600
Market Cap $73.5M
Description
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.